{"keywords":["BRAF","NRAS","expression profile","melanoma","metastasis","mutation","outcome","pathology","prognosis","treatment"],"publicationTypes":["Journal Article"],"abstract":"Accurately predicting disease outcome among patients bearing Stage III metastatic melanoma is complex. However, current advances in personalized medicine call for ever more precise prognostic assessments, as these have a significant impact not only on the design and analysis of clinical trials, but also on therapeutic decision-making.","title":"Identification of new prognostic biomarkers for Stage III metastatic melanoma patients.","pubmedId":"24228228"}